696 related articles for article (PubMed ID: 26423340)
1. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
2. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
3. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
4. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
5. Perspectives on research activity in the USA on Cancer Precision Medicine.
Bando H; Takebe N
Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
[TBL] [Abstract][Full Text] [Related]
6. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
8. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
[TBL] [Abstract][Full Text] [Related]
9. Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN).
Massett HA; Mishkin G; Moscow JA; Gravell A; Steketee M; Kruhm M; Han SH; Barry B; Montello M; Zwiebel J; Abrams JS; Doroshow JH; Ivy SP
Clin Cancer Res; 2019 Dec; 25(23):6925-6931. PubMed ID: 31439585
[TBL] [Abstract][Full Text] [Related]
10. NCI-MATCH launch highlights new trial design in precision-medicine era.
McNeil C
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
[No Abstract] [Full Text] [Related]
11. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
12. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
13. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Ivy SP; Siu LL; Garrett-Mayer E; Rubinstein L
Clin Cancer Res; 2010 Mar; 16(6):1726-36. PubMed ID: 20215542
[TBL] [Abstract][Full Text] [Related]
14. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
15. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
[TBL] [Abstract][Full Text] [Related]
16. American Society of Clinical Oncology Developing First Clinical Trial.
Brower V
J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
[No Abstract] [Full Text] [Related]
17. Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
Yada S; Hamada C
Pharm Stat; 2017 Nov; 16(6):433-444. PubMed ID: 28840635
[TBL] [Abstract][Full Text] [Related]
18. The changing landscape of phase I trials in oncology.
Wong KM; Capasso A; Eckhardt SG
Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
[TBL] [Abstract][Full Text] [Related]
19. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
20. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]